DOCSLIB.ORG

The Novel Interacting Partners of Viperin and Their Role in Establishing a Host Antiviral State

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Novel Interacting Partners of Viperin and Their Role in Establishing a Host Antiviral State The Novel Interacting Partners of Viperin and Their Role in Establishing a Host Antiviral State Onruedee Khantisitthiporn, M.Sc. Discipline of Molecular and Cellular Biology School of Biological Sciences The University of Adelaide A dissertation submitted to The University of Adelaide in candidature for the degree of Doctor of Philosophy in the Faculty of Sciences October 2017 Table of content LIST OF FIGURES ........................................................................................................ XI LIST OF TABLES ......................................................................................................... XV ABSTRACT .................................................................................................................. XVI DECLARATION.......................................................................................................... XIX ACKNOWLEDGEMENTS .......................................................................................... XX PRESENTATIONS AND PUBLICATIONS ARISING FROM THIS PHD ......... XXI MATERIALS PROVIDERS .................................................................................... XXIII ABBREVIATIONS USED ......................................................................................... XXV CHAPTER 1 ...................................................................................................................... 1 INTRODUCTION............................................................................................................. 1 1.1 Hepatitis C Virus......................................................................................................... 1 1.1.1 Discovery and Epidemiology ................................................................................. 1 1.1.2 Transmission .......................................................................................................... 2 1.1.3 Pathogenesis ........................................................................................................... 2 1.1.4 Treatment ............................................................................................................... 3 1.1.5 Classification and genotypes .................................................................................. 7 1.1.6 HCV genome and proteins ..................................................................................... 7 1.1.7 HCV virion/particles ............................................................................................ 15 1.1.8 HCV life cycle ..................................................................................................... 15 1.1.9 HCV model systems ............................................................................................ 20 1.1.9.1 HCV replicon systems .................................................................................. 21 ii 1.1.9.2 Infectious cell culture model ......................................................................... 23 1.2. Innate immune response to viral infection ............................................................ 24 1.2.1 Overview .............................................................................................................. 24 1.2.2 Innate immune response to RNA virus infection ................................................. 25 1.2.2.1 Cellular recognition of RNA viruses ............................................................ 25 1.2.2.1.1 Retinoic acid-inducible gene I (RIG-I) .................................................. 27 1.2.2.1.2 Melanoma differentiation-associated antigen 5 (MDA5) ...................... 29 1.2.2.1.3 Laboratory of genetics and physiology 2 (LGP2) ................................. 30 1.2.2.2 RIG-I-like receptors (RLRs) downstream signalling cascade ...................... 30 1.2.2.3 The interferon response to viral infection ..................................................... 36 1.2.2.4 Interferon Transduction Pathway .................................................................. 37 1.2.2.5 Interferon-stimulated genes (ISGs) ............................................................... 38 1.2.3 Innate immune recognition of HCV .................................................................... 38 1.2.3.1 Cellular recognition and downstream signalling events upon HCV infection ................................................................................................................................... 38 1.2.3.2 ISGs targeting HCV ...................................................................................... 39 1.3. Viperin ...................................................................................................................... 42 1.3.1 Viperin protein structure and subcellular localisation ......................................... 43 1.3.2 Regulation of viperin expression ......................................................................... 45 1.3.3 Antiviral functions of viperin............................................................................... 46 1.3.3.1 In vitro antiviral function .............................................................................. 47 1.3.3.2 In vivo antiviral function ............................................................................... 49 1.3.4 Evade and co-opt of viperin by viruses................................................................ 50 1.3.5 Roles of viperin in immune signalling ................................................................. 51 1.4 Peroxisomes and the antiviral response .................................................................. 55 1.4.1 Peroxisomes and their functions .......................................................................... 55 1.4.2 Peroxisomes and RLR signalling ......................................................................... 57 1.4.3 Peroxisome evasion by viruses ............................................................................ 60 1.5. Hypothesis and Aims ............................................................................................... 61 iii CHAPTER 2 .................................................................................................................... 62 MATERIALS AND METHODS ................................................................................... 62 2.1 General Molecular Methods .................................................................................... 62 2.1.1 Synthetic oligonucleotides (primers) ................................................................... 62 2.1.2 Bacterial transformation....................................................................................... 62 2.1.3 Small scale plasmid DNA extraction (Mini-preparation) .................................... 63 2.1.4 Large scale plasmid DNA extraction (Maxi-preparation) ................................... 63 2.1.5 Restriction endonuclease digestion ...................................................................... 64 2.1.6 Agarose gel electrophoresis ................................................................................. 65 2.1.7 DNA ligation ........................................................................................................ 65 2.1.8 DNA purification from agarose gel ..................................................................... 65 2.1.9 DNA sequencing .................................................................................................. 66 2.1.10 Total RNA extraction ......................................................................................... 67 2.1.11 Nucleic acid quantification ................................................................................ 67 2.1.12 First-strand cDNA synthesis .............................................................................. 68 2.1.13 Polymerase Chain Reaction (PCR) .................................................................... 68 2.1.14 Real-Time Quantitative PCR (qPCR) ................................................................ 69 2.1.15 Extraction of cellular proteins ............................................................................ 69 2.1.16 SDS-PAGE and protein transfer ........................................................................ 70 2.1.17 Western blotting ................................................................................................. 70 2.1.18 Co-immunoprecipitation .................................................................................... 71 2.1.19 Dual Renilla luciferase assay ............................................................................. 71 2.1.20 Duolink® In situ Proximity Ligation Assay ....................................................... 72 2.2 Yeast Two-Hybrid system ........................................................................................ 73 2.2.1 Competent yeast cell preparation ......................................................................... 74 2.2.2 Transformation ..................................................................................................... 74 2.2.2.1 Small scale transformation ............................................................................ 74 2.2.2.2 Library scale co-transformation .................................................................... 75 2.2.3 Plasmid DNA extraction from yeast cells ............................................................ 75 iv 2.2.4 Construction and testing of the bait (viperin) protein expression plasmid
Load more

Recommended publications
  • Supplementary Data
    Supplementary Data for Quantitative Changes in the Mitochondrial Proteome from Subjects with Mild Cognitive Impairment, Early Stage and Late Stage Alzheimer’s disease Table 1 - 112 unique, non-redundant proteins identified and quantified in at least two of the three analytical replicates for all three disease stages. Table 2 - MCI mitochondrial samples, Protein Summary Table 3 - MCI mitochondrial samples, Experiment 1 Table 4 - MCI mitochondrial samples, Experiment 2 Table 5 - MCI mitochondrial samples, Experiment 3 Table 6 - EAD Mitochondrial Study, Protein Summary Table 7 - EAD Mitochondrial Study, Experiment 1 Table 8 - EAD Mitochondrial Study, Experiment 2 Table 9 - EAD Mitochondrial Study, Experiment 3 Table 10 - LAD Mitochondrial Study, Protein Summary Table 11 - LAD Mitochondrial Study, Experiment 1 Table 12 - LAD Mitochondrial Study, Experiment 2 Table 13 - LAD Mitochondrial Study, Experiment 3 Supplemental Table 1. 112 unique, non-redundant proteins identified and quantified in at least two of the three analytical replicates for all three disease stages. Description Data MCI EAD LAD AATM_HUMAN (P00505) Aspartate aminotransferase, mitochondrial precursor (EC Mean 1.43 1.70 1.31 2.6.1.1) (Transaminase A) (Glutamate oxaloacetate transaminase 2) [MASS=47475] SEM 0.07 0.09 0.09 Count 3.00 3.00 3.00 ACON_HUMAN (Q99798) Aconitate hydratase, mitochondrial precursor (EC 4.2.1.3) Mean 1.24 1.61 1.19 (Citrate hydro-lyase) (Aconitase) [MASS=85425] SEM 0.05 0.17 0.18 Count 3.00 2.00 3.00 ACPM_HUMAN (O14561) Acyl carrier protein, mitochondrial
    [Show full text]
  • PEX2 Is the E3 Ubiquitin Ligase Required for Pexophagy During Starvation
    JCB: Article PEX2 is the E3 ubiquitin ligase required for pexophagy during starvation Graeme Sargent,1,6 Tim van Zutphen,7 Tatiana Shatseva,6 Ling Zhang,3 Valeria Di Giovanni,3 Robert Bandsma,2,3,4,5 and Peter Kijun Kim1,6 1Cell Biology Department, 2Department of Paediatric Laboratory Medicine, 3Physiology and Experimental Medicine Program, Research Institute, 4Division of Gastroenterology, Hepatology and Nutrition, and 5Centre for Global Child Health, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada 6Biochemistry Department, University of Toronto, Toronto, ON M5S 1A8, Canada 7Department of Pediatrics, Center for Liver, Digestive and Metabolic Diseases, University of Groningen, University Medical Center Groningen, 9700 AD Groningen, Netherlands Peroxisomes are metabolic organelles necessary for anabolic and catabolic lipid reactions whose numbers are highly dynamic based on the metabolic need of the cells. One mechanism to regulate peroxisome numbers is through an auto- phagic process called pexophagy. In mammalian cells, ubiquitination of peroxisomal membrane proteins signals pexo- phagy; however, the E3 ligase responsible for mediating ubiquitination is not known. Here, we report that the peroxisomal E3 ubiquitin ligase peroxin 2 (PEX2) is the causative agent for mammalian pexophagy. Expression of PEX2 leads to Downloaded from gross ubiquitination of peroxisomes and degradation of peroxisomes in an NBR1-dependent autophagic process. We identify PEX5 and PMP70 as substrates of PEX2 that are ubiquitinated during amino acid starvation. We also find that PEX2 expression is up-regulated during both amino acid starvation and rapamycin treatment, suggesting that the mTORC1 pathway regulates pexophagy by regulating PEX2 expression levels. Finally, we validate our findings in vivo using an animal model.
    [Show full text]
  • Table 2. Significant
    Table 2. Significant (Q < 0.05 and |d | > 0.5) transcripts from the meta-analysis Gene Chr Mb Gene Name Affy ProbeSet cDNA_IDs d HAP/LAP d HAP/LAP d d IS Average d Ztest P values Q-value Symbol ID (study #5) 1 2 STS B2m 2 122 beta-2 microglobulin 1452428_a_at AI848245 1.75334941 4 3.2 4 3.2316485 1.07398E-09 5.69E-08 Man2b1 8 84.4 mannosidase 2, alpha B1 1416340_a_at H4049B01 3.75722111 3.87309653 2.1 1.6 2.84852656 5.32443E-07 1.58E-05 1110032A03Rik 9 50.9 RIKEN cDNA 1110032A03 gene 1417211_a_at H4035E05 4 1.66015788 4 1.7 2.82772795 2.94266E-05 0.000527 NA 9 48.5 --- 1456111_at 3.43701477 1.85785922 4 2 2.8237185 9.97969E-08 3.48E-06 Scn4b 9 45.3 Sodium channel, type IV, beta 1434008_at AI844796 3.79536664 1.63774235 3.3 2.3 2.75319499 1.48057E-08 6.21E-07 polypeptide Gadd45gip1 8 84.1 RIKEN cDNA 2310040G17 gene 1417619_at 4 3.38875643 1.4 2 2.69163229 8.84279E-06 0.0001904 BC056474 15 12.1 Mus musculus cDNA clone 1424117_at H3030A06 3.95752801 2.42838452 1.9 2.2 2.62132809 1.3344E-08 5.66E-07 MGC:67360 IMAGE:6823629, complete cds NA 4 153 guanine nucleotide binding protein, 1454696_at -3.46081884 -4 -1.3 -1.6 -2.6026947 8.58458E-05 0.0012617 beta 1 Gnb1 4 153 guanine nucleotide binding protein, 1417432_a_at H3094D02 -3.13334396 -4 -1.6 -1.7 -2.5946297 1.04542E-05 0.0002202 beta 1 Gadd45gip1 8 84.1 RAD23a homolog (S.
    [Show full text]
  • Autophagy -   Autophagy
    EMBO Molecular Medicine cross-journal focus Autophagy - Autophagy EDITORS Andrea Leibfried Editor [email protected] | T + Andrea worked with Jan Lohmann on stem cell maintenance in the plant Arabidopsis before moving to the eld of trafcking. In she obtained her PhD from the Université Pierre et Marie Curie in Paris, for which she studied DE-Cadherin trafcking in Drosophila with Yohanns Bellaiche at the Curie Institute. She then went to Anne Ephrussi’s lab at the EMBL in Heidelberg to work on oocyte polarity and mRNA trafcking in Drosophila. Andrea joined The EMBO Journal in . Nonia Pariente Senior Editor [email protected] | T + Nonia joined EMBO Reports in August . She studied biochemistry and molecular biology in Madrid’s Autónoma University, where she also gained her PhD on the generation of new antiviral strategies against RNA viruses. She did a four-year post-doc at UCLA focusing on the development of new strategies for gene therapy. Céline Carret Editor [email protected] | T + Céline Carret completed her PhD at the University of Montpellier, France, characterising host immunodominant antigens to ght babesiosis, a parasitic disease caused by a unicellular EMBO Apicomplexan parasite closely related to the malaria agent Plasmodium. She further developed Molecular her post-doctoral career on malaria working at the Wellcome Trust Sanger Institute in Cambridge, Medicine UK and Instituto de Medicina Molecular in Lisbon, Portugal. Céline joined EMBO Molecular Medicine as a Scientic Editor in March . Maria Polychronidou Editor [email protected] | T + Maria received her PhD from the University of Heidelberg, where she studied the role of nuclear membrane proteins in development and aging.
    [Show full text]
  • Chikungunya Fever: Epidemiology, Clinical Syndrome, Pathogenesis
    Antiviral Research 99 (2013) 345–370 Contents lists available at SciVerse ScienceDirect Antiviral Research journal homepage: www.elsevier.com/locate/antiviral Review Chikungunya fever: Epidemiology, clinical syndrome, pathogenesis and therapy ⇑ Simon-Djamel Thiberville a,b, , Nanikaly Moyen a,b, Laurence Dupuis-Maguiraga c,d, Antoine Nougairede a,b, Ernest A. Gould a,b, Pierre Roques c,d, Xavier de Lamballerie a,b a UMR_D 190 ‘‘Emergence des Pathologies Virales’’ (Aix-Marseille Univ. IRD French Institute of Research for Development EHESP French School of Public Health), Marseille, France b University Hospital Institute for Infectious Disease and Tropical Medicine, Marseille, France c CEA, Division of Immuno-Virologie, Institute of Emerging Diseases and Innovative Therapies, Fontenay-aux-Roses, France d UMR E1, University Paris Sud 11, Orsay, France article info abstract Article history: Chikungunya virus (CHIKV) is the aetiological agent of the mosquito-borne disease chikungunya fever, a Received 7 April 2013 debilitating arthritic disease that, during the past 7 years, has caused immeasurable morbidity and some Revised 21 May 2013 mortality in humans, including newborn babies, following its emergence and dispersal out of Africa to the Accepted 18 June 2013 Indian Ocean islands and Asia. Since the first reports of its existence in Africa in the 1950s, more than Available online 28 June 2013 1500 scientific publications on the different aspects of the disease and its causative agent have been pro- duced. Analysis of these publications shows that, following a number of studies in the 1960s and 1970s, Keywords: and in the absence of autochthonous cases in developed countries, the interest of the scientific commu- Chikungunya virus nity remained low.
    [Show full text]
  • SV40 Large T Antigen Targets Multiple Cellular Pathways to Elicit Cellular Transformation
    Oncogene (2005) 24, 7729–7745 & 2005 Nature Publishing Group All rights reserved 0950-9232/05 $30.00 www.nature.com/onc SV40 large T antigen targets multiple cellular pathways to elicit cellular transformation Deepika Ahuja1,2, M Teresa Sa´ enz-Robles1,2 and James M Pipas*,1 1Department of Biological Sciences, University of Pittsburgh, Pittsburgh, PA 15260, USA DNA tumor viruses such as simian virus 40 (SV40) three proteins that are structural components of the express dominant acting oncoproteins that exert their virion (VP1, VP2, VP3) and two nonstructural proteins effects by associating with key cellular targets and termed large T antigen (T antigen) and small T antigen altering the signaling pathways they govern. Thus, tumor (t antigen). In addition, some members of the Polyoma- viruses have proved to be invaluable aids in identifying viridae encode additional proteins that are virus specific proteins that participate in tumorigenesis, and in under- or are encoded by a subset of viruses in the family. For standing the molecular basis for the transformed pheno- example, SV40 encodes three such proteins: agnopro- type. The roles played by the SV40-encoded 708 amino- tein, 17K T, and small leader protein. The genomes of acid large T antigen (T antigen), and 174 amino acid small all polyomaviruses can be divided into three elements: T antigen (t antigen), in transformation have been an early coding unit, a late coding unit, and a regulatory examined extensively. These studies have firmly estab- region (Figure 1). In a productive infection, expression lished that large T antigen’s inhibition of the p53 and Rb- of the early coding unit is effected by the cellular family of tumor suppressors and small T antigen’s action transcription apparatus and results in expression of the on the pp2A phosphatase, are important for SV40-induced large, small and 17K T antigens.
    [Show full text]
  • Research Article Label-Free Proteomics of the Fetal Pancreas Identifies Deficits in the Peroxisome in Rats with Intrauterine Growth Restriction
    Hindawi Oxidative Medicine and Cellular Longevity Volume 2019, Article ID 1520753, 15 pages https://doi.org/10.1155/2019/1520753 Research Article Label-Free Proteomics of the Fetal Pancreas Identifies Deficits in the Peroxisome in Rats with Intrauterine Growth Restriction Xiaomei Liu ,1 Yanyan Guo ,1 Jun Wang ,1,2 Linlin Gao ,3 and Caixia Liu 1 1Key Laboratory of Maternal-Fetal Medicine of Liaoning Province, Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang 110004, China 2Department of Obstetrics and Gynecology, Benxi Central Hospital of China Medical University, Benxi 117022, China 3Medical Research Center, Shengjing Hospital, China Medical University, Shenyang 110004, China Correspondence should be addressed to Xiaomei Liu; [email protected] Received 14 May 2019; Revised 31 August 2019; Accepted 9 September 2019; Published 3 November 2019 Guest Editor: Roberta Cascella Copyright © 2019 Xiaomei Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Aim. The objective of the present study was to identify differentially expressed proteins (DEPs) in the pancreas of a fetus with intrauterine growth restriction (IUGR) and to investigate the molecular mechanisms leading to adulthood diabetes in IUGR. Methods. The IUGR rat model was induced by maternal protein malnutrition. The fetal pancreas was collected at embryonic day 20 (E20). Protein was extracted, pooled, and subjected to label-free quantitative proteomic analysis. Bioinformatics analysis (GO and IPA) was performed to define the pathways and networks associated with DEPs. LC-MS results were confirmed by western blotting and/or quantitative PCR (q-PCR).
    [Show full text]
  • P53 and the Viral Connection: Back Into the Future ‡
    cancers Review p53 and the Viral Connection: Back into the Future ‡ Ronit Aloni-Grinstein 1,2,†, Meital Charni-Natan 1,†, Hilla Solomon 1 and Varda Rotter 1,* 1 Department of Molecular Cell Biology, Weizmann Institute of Science, 76100 Rehovot, Israel; [email protected] (R.A.-G.); [email protected] (M.C.-N.); [email protected] (H.S.) 2 Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Box 19, 74100 Ness-Ziona, Israel * Correspondence: [email protected]; Tel.: +972-8-9344501; Fax: +972-8-9342398 † These authors contributed equally to this work. ‡ This review is dedicated to the 25th memorial year of Prof. Yosef Aloni of the Weizmann Institute of Science, for his seminal and important pioneering research in the field of molecular biology of the SV40 virus. Received: 15 May 2018; Accepted: 1 June 2018; Published: 4 June 2018 Abstract: The discovery of the tumor suppressor p53, through its interactions with proteins of tumor-promoting viruses, paved the way to the understanding of p53 roles in tumor virology. Over the years, accumulating data suggest that WTp53 is involved in the viral life cycle of non-tumor-promoting viruses as well. These include the influenza virus, smallpox and vaccinia viruses, the Zika virus, West Nile virus, Japanese encephalitis virus, Human Immunodeficiency Virus Type 1, Human herpes simplex virus-1, and more. Viruses have learned to manipulate WTp53 through different strategies to improve their replication and spreading in a stage-specific, bidirectional way. While some viruses require active WTp53 for efficient viral replication, others require reduction/inhibition of WTp53 activity.
    [Show full text]
  • Antibody-Mediated Enhancement Aggravates Chikungunya Virus
    www.nature.com/scientificreports OPEN Antibody-mediated enhancement aggravates chikungunya virus infection and disease severity Received: 14 July 2017 Fok-Moon Lum 1,2, Thérèse Couderc3,4, Bing-Shao Chia1,8, Ruo-Yan Ong1,9, Zhisheng Her1,10, Accepted: 17 January 2018 Angela Chow5, Yee-Sin Leo5, Yiu-Wing Kam1, Laurent Rénia1, Marc Lecuit 3,4,6 & Published: xx xx xxxx Lisa F. P. Ng1,2,7 The arthropod-transmitted chikungunya virus (CHIKV) causes a fu-like disease that is characterized by incapacitating arthralgia. The re-emergence of CHIKV and the continual risk of new epidemics have reignited research in CHIKV pathogenesis. Virus-specifc antibodies have been shown to control virus clearance, but antibodies present at sub-neutralizing concentrations can also augment virus infection that exacerbates disease severity. To explore this occurrence, CHIKV infection was investigated in the presence of CHIKV-specifc antibodies in both primary human cells and a murine macrophage cell line, RAW264.7. Enhanced attachment of CHIKV to the primary human monocytes and B cells was observed while increased viral replication was detected in RAW264.7 cells. Blocking of specifc Fc receptors (FcγRs) led to the abrogation of these observations. Furthermore, experimental infection in adult mice showed that animals had higher viral RNA loads and endured more severe joint infammation in the presence of sub-neutralizing concentrations of CHIKV-specifc antibodies. In addition, CHIKV infection in 11 days old mice under enhancing condition resulted in higher muscles viral RNA load detected and death. These observations provide the frst evidence of antibody-mediated enhancement in CHIKV infection and pathogenesis and could also be relevant for other important arboviruses such as Zika virus.
    [Show full text]
  • NSP4)-Induced Intrinsic Apoptosis
    viruses Article Viperin, an IFN-Stimulated Protein, Delays Rotavirus Release by Inhibiting Non-Structural Protein 4 (NSP4)-Induced Intrinsic Apoptosis Rakesh Sarkar †, Satabdi Nandi †, Mahadeb Lo, Animesh Gope and Mamta Chawla-Sarkar * Division of Virology, National Institute of Cholera and Enteric Diseases, P-33, C.I.T. Road Scheme-XM, Beliaghata, Kolkata 700010, India; [email protected] (R.S.); [email protected] (S.N.); [email protected] (M.L.); [email protected] (A.G.) * Correspondence: [email protected]; Tel.: +91-33-2353-7470; Fax: +91-33-2370-5066 † These authors contributed equally to this work. Abstract: Viral infections lead to expeditious activation of the host’s innate immune responses, most importantly the interferon (IFN) response, which manifests a network of interferon-stimulated genes (ISGs) that constrain escalating virus replication by fashioning an ill-disposed environment. Interestingly, most viruses, including rotavirus, have evolved numerous strategies to evade or subvert host immune responses to establish successful infection. Several studies have documented the induction of ISGs during rotavirus infection. In this study, we evaluated the induction and antiviral potential of viperin, an ISG, during rotavirus infection. We observed that rotavirus infection, in a stain independent manner, resulted in progressive upregulation of viperin at increasing time points post-infection. Knockdown of viperin had no significant consequence on the production of total Citation: Sarkar, R.; Nandi, S.; Lo, infectious virus particles. Interestingly, substantial escalation in progeny virus release was observed M.; Gope, A.; Chawla-Sarkar, M. upon viperin knockdown, suggesting the antagonistic role of viperin in rotavirus release. Subsequent Viperin, an IFN-Stimulated Protein, studies unveiled that RV-NSP4 triggered relocalization of viperin from the ER, the normal residence Delays Rotavirus Release by Inhibiting of viperin, to mitochondria during infection.
    [Show full text]
  • Giorda KM, Raghava S, Hebert DN. the Simian Virus 40 Late Viral
    The Simian Virus 40 Late Viral Protein VP4 Disrupts the Nuclear Envelope for Viral Release Kristina M. Giorda, Smita Raghava and Daniel N. Hebert J. Virol. 2012, 86(6):3180. DOI: 10.1128/JVI.07047-11. Published Ahead of Print 11 January 2012. Downloaded from Updated information and services can be found at: http://jvi.asm.org/content/86/6/3180 http://jvi.asm.org/ These include: SUPPLEMENTAL MATERIAL http://jvi.asm.org/content/suppl/2012/02/14/86.6.3180.DC1.html REFERENCES This article cites 56 articles, 16 of which can be accessed free on June 8, 2012 by Univ of Massachusetts Amherst at: http://jvi.asm.org/content/86/6/3180#ref-list-1 CONTENT ALERTS Receive: RSS Feeds, eTOCs, free email alerts (when new articles cite this article), more» Information about commercial reprint orders: http://journals.asm.org/site/misc/reprints.xhtml To subscribe to to another ASM Journal go to: http://journals.asm.org/site/subscriptions/ The Simian Virus 40 Late Viral Protein VP4 Disrupts the Nuclear Envelope for Viral Release Kristina M. Giorda,a,b Smita Raghava,a and Daniel N. Heberta,b Department of Biochemistry and Molecular Biologya and Program in Molecular and Cellular Biology,b University of Massachusetts, Amherst, Massachusetts, USA Simian virus 40 (SV40) appears to initiate cell lysis by expressing the late viral protein VP4 at the end of infection to aid in virus Downloaded from dissemination. To investigate the contribution of VP4 to cell lysis, VP4 was expressed in mammalian cells where it was predomi- nantly observed along the nuclear periphery.
    [Show full text]
  • Peroxisomal Functions in the Lung and Their Role in the Pathogenesis of Lung Diseases
    Aus dem Institut für Anatomie und Zellbiologie der Justus-Liebig-Universität Gießen Leiter: Prof. Dr. Eveline Baumgart-Vogt Peroxisomal functions in the lung and their role in the pathogenesis of lung diseases Habilitationsschrift zur Erlangung der Venia legendi des Fachbereichs Medizin der Justus-Liebig-Universität Gießen vorgelegt von Srikanth Karnati Gießen 2018 Die nachfolgende Arbeit nimmt Bezug auf folgende Originalarbeiten: 1. Karnati S*, Graulich T, Oruqaj G, Pfreimer S, Seimetz M, Stamme C, Mariani TJ, Weissmann N, Mühlfeld C, Baumgart-Vogt E (2016). Postnatal development of the secretory cells of the distal airways, the bronchiolar club cells in the mouse lung: stereological and molecular biological studies. Cell and Tissue Research. Jun;364(3):543- 57. 2. Karnati S, Baumgart-Vogt E (2009) PeroXisomes in airway epithelia and future prospects of these organelles for pulmonary cell biology. Histochem Cell Biol. Apr: 131(4):447-54. 3. Karnati S, Lüers G, Pfreimer S and Baumgart-Vogt E (2013) Manganese SuperoXide dismutase 2 (MnSOD) is localized to mitochondria but not in peroXisomes. Histochemistry and Cell Biology, Aug:140(2):105-17 4. Karnati S, Palaniswamy S, Alam MR, Oruqaj G, Stamme C, Baumgart-Vogt E (2015) C22- bronchial and T7-alveolar epithelial cell lines of the immortomouse are eXcellent murine cell culture model systems to study pulmonary peroXisome biology and metabolism. Histochemistry and Cell Biology Mar;145(3):287-304. 5. Oruqaj G§, Karnati S§, Vijayan V, Kotarkonda LK, Boateng E, Zhang W, Ruppert C, Günther A, Shi W, Baumgart-Vogt E (2015) Compromised peroXisomes in idiopathic pulmonary fibrosis, a vicious cycle inducing a higher fibrotic response via TGF-β signaling.
    [Show full text]